Ironwood Pharmaceuticals Inc
Radius Continued to Fall despite Positive Data on Osteoporosis
Radius closed at $49.80 on October 13, 2015. During this period, it fell ~34%. Radius is trading below the 20-day, 50-day, and 100-day moving averages.
Chimerix Falls 80% following Phase 3 Trial of Brincidofovir
Chimerix closed at $6.62, and its market-cap fell from $1.6 billion to $305 million on December 28, 2015.
Arena Rose 14% in XBI’s Small-Cap Space
Arena Pharmaceuticals (ARNA) rose 14% on November 2, 2015. The stock went up on high trading volumes with ~4.7 million shares being traded.
Here’s What Tesaro’s Valuation Trend Indicates
Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.
How Is Bausch Health’s Salix Pharmaceuticals Positioned?
Bausch Health Companies’ (BHC) wholly-owned subsidiary Salix Pharmaceuticals reported revenue of $441 million in the second quarter.
What Does Nektar Therapeutics’ Valuation Trend Indicate?
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
What’s the Upside Potential of Nektar Therapeutics?
Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating.
The Financial Performance of Sucampo Pharmaceuticals
Sucampo Pharmaceuticals (SCMP) generated revenues of $61.2 million in 3Q17 compared with $57 million in 3Q16.
Sucampo Pharmaceuticals’ Amitiza: Its Competitive Landscape
In the branded prescription category, Amitiza competes with Ironwood Pharmaceuticals (IRWD) and Allergan’s (AGN) Linzess.
Synergy Pharmaceuticals Is Facing These Risks This November
Synergy only started earning revenues after the launch of Trulance in March 2017. Prior to that, Synergy hadn’t earned any revenues.
Behind Synergy Pharmaceuticals’ Financials Today
Synergy (SGYP) incurred R&D (research and development) expenses of ~$90 million, $78 million, and $ 83 million in fiscal 2016, 2015, and 2014, respectively.
An Overview of Trulance: Synergy Pharmaceuticals’ First Commercialized Drug
Since its launch, Synergy’s (SGYP) Trulance sales have been steadily rising. In 3Q17, more than 25,000 prescriptions were filled for the drug.
XBI’s Holdings: What’s the Trend in Its Moving Averages?
On June 15, 2016, XBI closed at $54.74. It was trading above its 20-day and 50-day moving averages. XBI’s 20-day moving average is $56.30.
AstraZeneca’s Recent Products: Approvals and Designations
AstraZeneca’s (AZN) recent product developments include four drugs that have recently received approvals from regulatory authorities. Four other drugs have received regulatory designations.
Will AstraZeneca’s Corporate Developments Help?
In this part, we’ll look at some of AstraZeneca’s corporate developments. It entered into some collaborative agreements in 1Q16, including drug development and commercialization rights.
IBB Small-Caps Reduce Negative Returns in December
The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.
Immunogen Topped the Small-Cap Stocks with High Volumes
Immunogen rose by 7.2% as of November 25, 2015. The stock rose on the high trading volume. It closed at $13.76. It passed the 100-day moving average price.
Celldex Leads the Small-Cap Stocks in IBB
Celldex rose by 12.3%. This is the second consecutive trading session the stock gained after it presented varlilumab data at the SITC Annual Meeting 2015.
IBB’s Top Ten Small-Cap Stocks Rose Handsomely
The top ten small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) outperformed the IBB and the SPDR S&P 500 ETF (SPY) with an average return of 6.25%.